Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: A time-motion study;Analisi dei costi di trattamento dell'osteolisi tumorale con acido zoledronico e pamidronato per via endovenosa: Uno studio tempi & metodi

Recenti Progressi in Medicina

Volumn 98, Issue 1, 2007, Pages 12-15

  Schivazappa, Chiara ^a   Baldini, Editta ^b   Cortesi, Enrico ^c   Dauria, Giuliana ^c   Roila, Fausto ^d   Berto, Patrizia ^a  

^a Pbe Consulting   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c POLICLINICO UMBERTO I   (Italy)

^d POLICLINICO MONTELUCE   (Italy)

Author keywords

Medical care costs; Microcosting technique; Pamidronate; Time motion study; Tumor induced osteolysis; Zoledronic acid

Indexed keywords

PAMIDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; ITALY; OSTEOLYSIS; PALLIATIVE THERAPY; TUMOR;

BONE DENSITY CONSERVATION AGENTS; COSTS AND COST ANALYSIS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; NEOPLASMS; OSTEOLYSIS; TIME AND MOTION STUDIES;

EID: 33846993725     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Terat Rev 2001; 27: 165-76.
2. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-57.
3. Body JJ. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 2003; 97 (3 suppl): 859-65.
4. Delea T, McKiernan J, Liss M, et al. Effects of skeletal complications on total medical care costs in women with bone metastases of breast cancer. Bone 2004; 34 (suppl 1): S86 (abstract 68).
5. Hillner BE. Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease. Semin Oncol 2001; 28 (4 suppl 11): 64-8.
6. Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000; 18: 72-9.
7. Reed SD, Radeva JI, Glendenning GA, Saad F, Schulman KA. Cost-effectiveness of zoledronic acid for the prevention of skeletal complication in patients with prostate cancer. J Urol 2004; 171: 1537-42.
8. DesHarnais Castel L, Bajwa K, Markle JP, Timbie JW, Zacker C, Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001; 9: 545-51.
9. Joshua DE, Chern B, Dalley D, Pittman K, Kingsford Smith D, Lowe S, et al. Resource use by zoledronic acid or pamidronate infusions in multiple myeloma and cancer. Blood 2002;100: 496b. Abstract 5571.
10. Maxwell C, Swift R, Goode M, Doane L, Rogers M. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. Clin J Oncol Nurs 2003; 7: 403-8.
11. Florea NR, Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP. Cost analysis of continuous versus intermittent infusion of piperacillin- tazobactam: a time-motion study. Am J Health Syst Pharm 2003; 60: 2321-12.
12. Pellissier JM, Coplan PM, Jackson LA, May JE. The effect of additional shots on the vaccine administration process: results of a time-motion study in 2 settings. Am J Managed Care 2000; 6: 1038-44.
13. Guest JF, Clegg JP, Davie AM, McCloskey E. Cost and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK. Curr Med Res Opin 2005; 21: 805-15.